The German government is to take a 23% stake in CureVac AG, which is developing an mRNA-based vaccine against COVID-19.
The federal government insists that the €300m ($338
Coronavirus Update: FDA Pulls Hydroxychloroquine Emergency Authorization, Germany Acquires Stake In CureVac
Praise And Blame For Actions On Controversial Drug
Plus news on the German government's decision to by a 23% stake in mRNA vaccines company CureVac, and Lilly taking Olumiant into Phase III.
More from COVID-19
More from Scrip
• By
Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.
• By
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
• By
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.